Hirokazu Shoji

16PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyCancer geneticsMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 06, 2026
Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

|Mar 19, 2026
Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor.

Yukiko Shimoda Igawa, Tatsuya Yoshida, Jun Sato

|Mar 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

|Jan 22, 2026
Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies.

Hirokazu Shoji, Narikazu Boku, Jun Adachi

|Jan 15, 2026
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.

Nozomu Ogura, Hidekazu Hirano, Kouya Shiraishi

Pageof 3

Frequent Collaborators

4 joint publications

Kengo Nagashima

4 joint publications

Hidekazu Hirano

3 joint publications

Narikazu Boku

3 joint publications

Ken Kato